These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
430 related items for PubMed ID: 18379353
21. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. Takenaka D, Ohno Y, Matsumoto K, Aoyama N, Onishi Y, Koyama H, Nogami M, Yoshikawa T, Matsumoto S, Sugimura K. J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984 [Abstract] [Full Text] [Related]
22. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, Sugimura K. AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481 [Abstract] [Full Text] [Related]
23. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Takano A, Oriuchi N, Tsushima Y, Taketomi-Takahashi A, Nakajima T, Arisaka Y, Higuchi T, Amanuma M, Endo K. Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417 [Abstract] [Full Text] [Related]
28. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings. Kim SC, Machac J, Krynyckyi BR, Knesaurek K, Krellenstein D, Schultz B, Gribetz A, DePalo L, Teirstein A, Kim CK. Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030 [Abstract] [Full Text] [Related]
29. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results. Heusch P, Buchbender C, Köhler J, Nensa F, Beiderwellen K, Kühl H, Lanzman RS, Wittsack HJ, Gomez B, Gauler T, Schuler M, Forsting M, Bockisch A, Antoch G, Heusner TA. Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802 [Abstract] [Full Text] [Related]
30. Overestimated value of (18)F-FDG PET/CT to diagnose pulmonary nodules: Analysis of 298 patients. Li S, Zhao B, Wang X, Yu J, Yan S, Lv C, Yang Y. Clin Radiol; 2014 Aug; 69(8):e352-7. PubMed ID: 24877581 [Abstract] [Full Text] [Related]
31. Dynamic MRI, dynamic multidetector-row computed tomography (MDCT), and coregistered 2-[fluorine-18]-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/CT: comparative study of capability for management of pulmonary nodules. Ohno Y, Koyama H, Takenaka D, Nogami M, Maniwa Y, Nishimura Y, Ohbayashi C, Sugimura K. J Magn Reson Imaging; 2008 Jun; 27(6):1284-95. PubMed ID: 18504748 [Abstract] [Full Text] [Related]
32. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G, Stahl A. Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355 [Abstract] [Full Text] [Related]
33. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? Ohba Y, Nomori H, Mori T, Ikeda K, Shibata H, Kobayashi H, Shiraishi S, Katahira K. J Thorac Cardiovasc Surg; 2009 Aug; 138(2):439-45. PubMed ID: 19619793 [Abstract] [Full Text] [Related]
34. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):200-8. PubMed ID: 18779960 [Abstract] [Full Text] [Related]
36. Solitary pulmonary nodules: Comparison of dynamic first-pass contrast-enhanced perfusion area-detector CT, dynamic first-pass contrast-enhanced MR imaging, and FDG PET/CT. Ohno Y, Nishio M, Koyama H, Seki S, Tsubakimoto M, Fujisawa Y, Yoshikawa T, Matsumoto S, Sugimura K. Radiology; 2015 Feb; 274(2):563-75. PubMed ID: 25203128 [Abstract] [Full Text] [Related]
37. DW MRI at 3.0 T versus FDG PET/CT for detection of malignant pulmonary tumors. Zhang J, Cui LB, Tang X, Ren XL, Shi JR, Yang HN, Zhang Y, Li ZK, Wu CG, Jian W, Zhao F, Ti XY, Yin H. Int J Cancer; 2014 Feb 01; 134(3):606-11. PubMed ID: 23893610 [Abstract] [Full Text] [Related]
38. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX, Cheng J, Xu WG, Dai D, Song XY, Ma WC, Zhu L, Zhu X. Zhonghua Zhong Liu Za Zhi; 2012 May 01; 34(5):364-8. PubMed ID: 22883458 [Abstract] [Full Text] [Related]
39. FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient. Nakajo M, Nakajo M, Kajiya Y, Tani A, Kamiyama T, Yonekura R, Fukukura Y, Matsuzaki T, Nishimoto K, Nomoto M, Koriyama C. Clin Nucl Med; 2012 May 01; 37(5):475-80. PubMed ID: 22475897 [Abstract] [Full Text] [Related]
40. 18F-FDG PET/CT in immunocompetent patients with primary central nervous system lymphoma: Differentiation from glioblastoma and correlation with DWI. Zhou W, Wen J, Hua F, Xu W, Lu X, Yin B, Geng D, Guan Y. Eur J Radiol; 2018 Jul 01; 104():26-32. PubMed ID: 29857862 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]